Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2003

View Archived Issues

Dual adenosine A1/A2A antagonists and their use reported by Fujisawa

Novel VEGFR kinase inhibitors identified by Novartis researchers

Immunogenic peptides with utility in HIV infection therapy

Pharmacia scientists claim new alpha7 nAChR agonists in recent patent

New IKK inhibitors in early development at Roche

Amine salts of alphavbeta3 integrin antagonist covered by Merck patent

Wyeth presents new estrogenic agents with utility in osteoporosis, cancer, IBD, etc.

Fujisawa licenses carperitide in North America and Europe

Revimid demonstrates potential in myelodysplastic syndromes

ICN to make tender offer for outstanding shares of Ribapharm

Anika seeks FDA approval for Orthovisc

Nicotine increases muscle girth, decreases body weight and reduces appetite in mice

RxKinetix acquires exclusive rights to RK-0202

Grant supports development of virus cell-based assay for anti-HIV drug discovery

PDL initiates trial of anti-alpha5beta1 integrin antibody in solid tumors

Nuvion development targeted for ulcerative colitis

Oralin set to enter phase IIb shortly

Enrollment completed in Atrisone phase III studies

Baxter launches Aralast

Tricyclic quinoxalines as potential new agents for restenosis and cancer

Advexin able to stop progression of advanced esophageal cancer

AP-2238, the prototype of a novel class of AD therapeutics

Phase I clinical trial results for Bay-43-9006 summarized at ASCO

Phase I clinical evaluation initiated for HIV-based lentiviral vector from VIRxSYS

EMD-72000 shows good tolerability and evidence of antitumor activity in phase I trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...